Procter & Gamble Health Limited has revised the agenda for its upcoming board meeting, adding consideration of interim dividend declaration to the scheduled proceedings. The company communicated this update to stock exchanges on January 21, 2026.

Board Meeting Agenda Revision

The healthcare company has expanded the scope of its board meeting scheduled for February 6, 2026, to include deliberation on interim dividend declaration for Financial Year 2025-26. This addition comes as a revision to the original meeting agenda that was previously communicated to exchanges on December 26, 2025.

Regulatory Communication

The company formally notified both major Indian stock exchanges about this agenda revision. The communication was addressed to:

• BSE Limited (Scrip Code: 500126)
• National Stock Exchange of India Limited (Scrip Code: PGHL)

Company Secretary Zeal Rupani signed the official communication, which was digitally authenticated on January 21, 2026, at 12:09:05 IST. The letter specifically referenced the earlier communication dated December 26, 2025, ensuring regulatory compliance and transparency.

Corporate Governance

This revision demonstrates the company's adherence to regulatory requirements for timely disclosure of material information to shareholders and market participants. The formal notification process ensures all stakeholders are informed about potential dividend considerations well in advance of the board meeting.

Procter & Gamble Health Limited (PGHL) has announced its unaudited financial results for the second quarter of the fiscal year 2025-26, ending September 30, 2025. The company has demonstrated strong performance with growth in both top-line and bottom-line figures.

Financial Highlights

*All figures in crores except for Earnings Per Share

Key Performance Indicators

• Sales Growth: PGHL reported sales of ₹319.00 crores, marking a 3% increase compared to the same quarter last year.
• Profit After Tax (PAT): The company's PAT stood at ₹89.00 crores, up by 8% year-over-year.
• Half-Year Performance: For the six-month period ended September 30, 2025, PGHL recorded a revenue of ₹109.30 crores with a net profit of ₹154.80 crores.
• Cash Position: Cash and cash equivalents increased to ₹279.30 crores as of September 30, 2025, from ₹182.30 crores as of March 31, 2025, indicating strong liquidity.

Strategic Initiatives

Mr. Milind Thatte, Managing Director of P&G Health India, attributed the sustained growth momentum to several strategic efforts:

1. Brand Communication: Strategic consumer communication initiatives for key brands like Evion and Seven Seas.
2. Product Innovation: Introduction of new products such as Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream.
3. Supply Chain Enhancement: Continued strengthening of supply chain capabilities to meet evolving consumer and healthcare professional needs.
4. Market Approach: Focus on superior brand building, go-to-market initiatives, and science-backed innovations.

Company Overview

Procter & Gamble Health Limited is a leading player in India's vitamins, minerals, and supplements (VMS) market. The company manufactures and markets VMS products for a healthy lifestyle and improved quality of life, with a portfolio including popular brands such as Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.

Market Response

The financial results were approved by the PGHL Board of Directors at a meeting held on November 5, 2025. The company's performance reflects its strong market position and effective strategy execution in a competitive healthcare products landscape.

Conclusion

Procter & Gamble Health Limited's Q2 FY2026 results demonstrate the company's ability to drive growth through strategic initiatives and product innovations. The balanced growth across both revenue and profitability metrics indicates a robust business model and effective management of market dynamics in the healthcare and consumer goods sectors.